ST-266 is under clinical development by Noveome Biotherapeutics and currently in Phase II for Necrotizing Enterocolitis. According to GlobalData, Phase II drugs for Necrotizing Enterocolitis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ST-266 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ST-266 overview

ST-266 is under development for the treatment of ocular hypertension, radiation-induced dermatitis, dry eye syndrome, periodontitis and optic neuritis, the most common presenting sign of multiple sclerosis (MS), necrotizing enterocolitis, cataract surgery complications (ophthalmology), erythema, glaucoma, Trigeminal Neuralgia (Tic Douloureux), chronic traumatic encephalopathy (CTE), diabetic retinopathy, diabetic macular edema. The drug candidate is administered through ophthalmic, topical, intraocular, buccal, nasal and lingual routes of administration. It is an amniotic membrane derived cellular cytokine solution (ACCS). It is developed based on a proprietary technology platform derived from human placental cells. The drug candidate was also under development for the treatment of deep burns (diabetic subjects), and partial thickness burns (non-diabetics subjects).

It is also under development for the treatment of gingivitis, allergic conjunctivitis, emphysema, cytokine storm (CS) in patients caused by the coronavirus disease (COVID-19), trauma, age-related macular degeneration (AMD), traumatic brain injury, persistent corneal epithelial defects and optic nerve/retinal diseases, sepsis and injuries.

Noveome Biotherapeutics overview

Noveome Biotherapeutics formerly Stemnion, is a biopharmaceutical company advancing ST266, a multi-targeted secretome containing biologically active proteins and other factors crucial to neuroprotection, the modulation of inflammation, cell recovery and healing. Noveome Biotherapeutics is headquartered in Pittsburgh, Pennsylvania, the US.

For a complete picture of ST-266’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.